BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martínez S, Pérez L, Galmarini CM, Aracil M, Tercero JC, Gago F, Albella B, Bueren JA. Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. Br J Pharmacol 2013;170:871-82. [PMID: 23937566 DOI: 10.1111/bph.12331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Xu L, Hu Y, Li Y, Zhang L, Ai H, Liu Y, Liu H. In vitro DNA binding studies of lenalidomide using spectroscopic in combination with molecular docking techniques. Journal of Molecular Structure 2018;1154:9-18. [DOI: 10.1016/j.molstruc.2017.10.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
2 Larsen AK, Galmarini CM, D’incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol 2016;77:663-71. [DOI: 10.1007/s00280-015-2918-1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
3 Newman DJ, Cragg GM. Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Mar Drugs 2014;12:255-78. [PMID: 24424355 DOI: 10.3390/md12010255] [Cited by in Crossref: 160] [Cited by in F6Publishing: 134] [Article Influence: 20.0] [Reference Citation Analysis]
4 Singh IP, Shah P. Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015). Expert Opin Ther Pat 2017;27:17-36. [PMID: 27623022 DOI: 10.1080/13543776.2017.1236084] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
5 Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget 2016;7:25885-901. [PMID: 27029031 DOI: 10.18632/oncotarget.8292] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]